SCHEMBL3777229

SCHEMBL3777229

COc1cccc(C2(O)CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.60
MEN1 O00255 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
ALDH1A1 P00352 5/20 0.57
HTR1D P28221 1/20 0.47
TSHR P16473 1/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
GRIN2B Q13224 1/20 0.45
POLB P06746 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770400 0.88 KMT2A (0.54) KMT2AMEN1SMN1; SMN2ALDH1A1TSHR
SCHEMBL3772438 0.87 NPSR1 (0.44) KMT2AMEN1SMN1; SMN2ALDH1A1OPRM1
SCHEMBL3765913 0.86 ALDH1A1 (0.57) KMT2AMEN1SMN1; SMN2ALDH1A1TSHR
SCHEMBL13005270 0.85 ALDH1A1 (0.48) KMT2AMEN1SMN1; SMN2ALDH1A1OPRM1
SCHEMBL3774342 0.85 NPSR1 (0.46) KMT2AMEN1SMN1; SMN2ALDH1A1TSHR
SCHEMBL13005268 0.83 HTT (0.49) KMT2AMEN1SMN1; SMN2ALDH1A1OPRM1
SCHEMBL3772583 0.82 OPRL1 (0.58) KMT2AMEN1SMN1; SMN2TSHROPRM1
SCHEMBL3765124 0.82 TSHR (0.59) KMT2AMEN1SMN1; SMN2ALDH1A1TSHR
SCHEMBL3770061 0.81 SIGMAR1 (0.63) KMT2AMEN1ALDH1A1TSHROPRK1
SCHEMBL3776429 0.81 GAA (0.61) SMN1; SMN2ALDH1A1POLBHRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885MEN1 3270/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.